These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 14703935)

  • 1. Transfusion-associated graft vs. host disease after donor-specific leukocyte transfusion before kidney transplantation.
    van der Mast BJ; van den Dorpel MA; Drabbels JJ; Claas FH; Weimar W
    Clin Transplant; 2003 Oct; 17(5):477-83. PubMed ID: 14703935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transfusion-associated graft-versus-host disease in immunocompetent patients: a self-protective mechanism.
    van der Mast BJ; Hornstra N; Ruigrok MB; Claas FH; van Rood JJ; Lagaaij EL
    Lancet; 1994 Mar; 343(8900):753-7. PubMed ID: 7907730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnosis of transfusion-associated graft-vs.-host disease: the importance of short tandem repeat analysis.
    Sage D; Stanworth S; Turner D; Navarrete C
    Transfus Med; 2005 Dec; 15(6):481-5. PubMed ID: 16359419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies.
    Spitzer TR; McAfee S; Sackstein R; Colby C; Toh HC; Multani P; Saidman S; Weyouth DW; Preffer F; Poliquin C; Foley A; Cox B; Andrews D; Sachs DH; Sykes M
    Biol Blood Marrow Transplant; 2000; 6(3A):309-20. PubMed ID: 10905768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lung transplantation complicated by graft-versus-host disease and confounded by incidental transfusion-associated macrochimerism.
    Pavenski K; Kamel-Reid S; Wei C; Cserti-Gazdewich CM
    Transfusion; 2008 Oct; 48(10):2190-6. PubMed ID: 18631170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HLA homozygosity and shared HLA haplotypes in the development of transfusion-associated graft-versus-host disease.
    Shivdasani RA; Anderson KC
    Leuk Lymphoma; 1994 Oct; 15(3-4):227-34. PubMed ID: 7866271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fatal transfusion-associated graft-versus-host disease with concomitant immune hemolysis in a group A combat trauma patient resuscitated with group O fresh whole blood.
    Gilstad C; Roschewski M; Wells J; Delmas A; Lackey J; Uribe P; Popa C; Jardeleza T; Roop S
    Transfusion; 2012 May; 52(5):930-5. PubMed ID: 21981662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fatal graft-versus-host disease associated with transfusions of HLA-matched, HLA-homozygous platelets from unrelated donors.
    Benson K; Marks AR; Marshall MJ; Goldstein JD
    Transfusion; 1994 May; 34(5):432-7. PubMed ID: 8191569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Transfusion-associated graft-vs-host disease].
    Lillevang ST; Kristensen T
    Ugeskr Laeger; 1992 Oct; 154(43):2964-8. PubMed ID: 1462384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation.
    Dey BR; McAfee S; Colby C; Sackstein R; Saidman S; Tarbell N; Sachs DH; Sykes M; Spitzer TR
    Biol Blood Marrow Transplant; 2003 May; 9(5):320-9. PubMed ID: 12766882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fatal Graft-Versus-Host Disease Following Adult-To-Adult Living Donor Liver Transplantation From an HLA Nonhomozygous Donor.
    Yu YD; Kim DS; Ha N; Jung SW; Han JH; Kim JY; Park SH; Cho YJ
    Prog Transplant; 2016 Dec; 26(4):394-396. PubMed ID: 27555077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transfusion-associated graft-versus-host disease in a liver transplant recipient: an unusual presentation and review of the literature.
    O'Brien KL; Pereira SE; Wagner J; Shadman M; Hendrie P; Nelson K; Gernsheimer TB; Price T; Reyes JD; Nester T
    Transfusion; 2013 Jan; 53(1):174-80. PubMed ID: 22563807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased apoptosis of immunoreactive host cells and augmented donor leukocyte chimerism, not sustained inhibition of B7 molecule expression are associated with prolonged cardiac allograft survival in mice preconditioned with immature donor dendritic cells plus anti-CD40L mAb.
    Lu L; Li W; Zhong C; Qian S; Fung JJ; Thomson AW; Starzl TE
    Transplantation; 1999 Sep; 68(6):747-57. PubMed ID: 10515374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of donor-derived host-reactive cytolytic and helper T cells with outcome following alternative donor T cell-depleted bone marrow transplantation.
    Keever-Taylor CA; Passweg J; Kawanishi Y; Casper J; Flomenberg N; Baxter-Lowe LA
    Bone Marrow Transplant; 1997 May; 19(10):1001-9. PubMed ID: 9169644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring systemic donor lymphocyte macrochimerism to aid the diagnosis of graft-versus-host disease after liver transplantation.
    Taylor AL; Gibbs P; Sudhindran S; Key T; Goodman RS; Morgan CH; Watson CJ; Delriviere L; Alexander GJ; Jamieson NV; Bradley JA; Taylor CJ
    Transplantation; 2004 Feb; 77(3):441-6. PubMed ID: 14966423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tissue Damage Caused by Myeloablative, but Not Non-Myeloablative, Conditioning before Allogeneic Stem Cell Transplantation Results in Dermal Macrophage Recruitment without Active T-Cell Interaction.
    van Balen P; van der Zouwen B; Kruisselbrink AB; Eefting M; Szuhai K; Jordanova ES; Falkenburg JHF; Jedema I
    Front Immunol; 2018; 9():331. PubMed ID: 29535719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transfusion-associated graft-versus-host disease.
    Rühl H; Bein G; Sachs UJ
    Transfus Med Rev; 2009 Jan; 23(1):62-71. PubMed ID: 19056035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transfusion-associated graft-versus-host disease in immunocompetent patients: report of a fatal case associated with transfusion of blood from a second-degree relative, and a survey of predisposing factors.
    Petz LD; Calhoun L; Yam P; Cecka M; Schiller G; Faitlowicz AR; Herron R; Sayah D; Wallace RB; Belldegrun A
    Transfusion; 1993 Sep; 33(9):742-50. PubMed ID: 8105567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of immunoregulatory donor T cells in suppression of graft-versus-host disease following donor leukocyte infusion therapy.
    Johnson BD; Becker EE; LaBelle JL; Truitt RL
    J Immunol; 1999 Dec; 163(12):6479-87. PubMed ID: 10586039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.